[fr] La radiothérapie après prostatectomie pour un cancer de prostate est un traitement recommandé en cas de «récidive biochimique» (ré-élévation du PSA) après l’opération. Des controverses quant à son utilisation optimale, sa réalisation, et ses toxicités font régulièrement l’objet de discussion, que ce soit au sein des sociétés scientifiques ou lors des concertations oncologiques multidisciplinaires. Cet article a pour but de faire l’état des lieux des connaissances actuelles et des recommandations existantes afin de guider nos réflexions et prises de décision concernant les traitements des patients présentant un cancer de la prostate.
Disciplines :
Oncologie
Auteur, co-auteur :
Lamande, Maréva ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiothérapie
LALLEMAND, François ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiothérapie
Waltregny, David ; Université de Liège - ULiège > Département des sciences cliniques > Urologie
Coucke, Philippe ; Université de Liège - ULiège > Département des sciences cliniques ; Université de Liège - ULiège > Département des sciences cliniques > Radiothérapie ; Université de Liège - ULiège > Unités de recherche interfacultaires > Research Unit for a life-Course perspective on Health and Education (RUCHE)
Langue du document :
Français
Titre :
La place de la radiothérapie après une prostatectomie dans les cancers de la prostate en 2024
Titre traduit :
[en] The place of radiation therapy following radical prostatectomy in 2024
Belgian Cancer Registry. Cancer Fact Sheet. Prostate Cancer. Consulté le 20/03/2023. Available from: http://kankerregister.org/media/docs/CancerFactSheets/2020/Cancer_Fact_Sheet_ProstateCancer_2020.pdf. Consulté le 20/03/2023.
Fondation contre le cancer. Cancer de la prostate-généralités. Disponible sur: https://www.cancer.be/les-cancers/types-decancers/cancer-de-la-prostate. Consulté le 20/03/2023.
Mottet N, van den Bergh RCN, Briers E,, et al. EAU-EANMESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79:243-62.
Cornford P, van den Bergh RC, Briers E, et al. EAU-EANMESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021;79:263-82.
Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw 2022;20:1288-98.
Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N England J Med 2016;375:1415-24.
Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N England J Med 2023;388:1547-58..
Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8.
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018-27.
Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020;396:1422-31.
Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020;21:1331-40.
Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 2020;396:1413-21.
Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020;21:1341-52.
Tilki D, Chen MH, Wu J, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol 2023;41:2428-35.
Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016;34:3648-54.
Ghadjar P, Hayoz S, Bernhard J, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. Eur Urol 2021;80:306-15.
Robin S, Jolicoeur M, Palumbo S, et al. Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the francophone group of urological radiation therapy. Int J Radiat Oncol Biol Phys 2021;109:1243-53.
Dal Pra A, Dirix P, Khoo V, et al. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clin Transl Radiat Oncol 2023;41:100638.
De Meerleer G, Berghen C, Briganti A, et al. Elective nodal radiotherapy in prostate cancer. Lancet Oncol 2021;22:e348-57.
Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 2021;39:1234-42.
Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/ RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 2022;399:1886-901.
Sujenthiran A, Parry MG, Dodkins J, et al. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study. Clin Transl Radiat Oncol 2023;40:100622.
López Campos F, Sancho Pardo G, Maldonado Pijoan X, et al. Is hypofractionation acceptable for prostate bed radiotherapy? Urol Oncol 2021;39:346-50
Chin S, Fatimilehin A, Walshaw R, et al. Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure. Int J Radiat Oncol Biol Phys 2020;107:288-96.
Franzese C, Badalamenti M, Baldaccini D, et al. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlenther Onkol 2021;197:133-40.
Leite ET, Ramos CC, Ribeiro VA, et al. Hypofractionated radiation therapy to the prostate bed with intensity-modulated radiation therapy (IMRT): a phase 2 trial. Int J Radiat Oncol Biol Phys 2021;109:1263-70.
Zaffuto E, Gandaglia G, Fossati N, et al. Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer. J Urol 2017;197(3Part1):669-75.
Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017;376:417-28.
Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016;17:747-56.
